CEAC's relationship with Oncimmune
The Centre of Excellence for Autoimmunity in Cancer might be new, but its origins lie in research carried out over a decade by The University of Nottingham under Professor John Robertson, and which led to breakthroughs in the potential early detection of some cancers.
To develop practical applications of these research findings – such as a test that can save lives – a spin-out company called Oncimmune was developed.
Bringing the test to market
Oncimmune’s success in bringing the EarlyCDT®-Lung test to market has given it the ability to grant back to the University fruits of this venture.
CEAC has secured exclusive access to this platform from Oncimmune for academic research. The formation of CEAC has already attracted some of the foremost academics from around the world to request access to the technology in collaborative studies.
Life-saving research
This truly is a unique opportunity for cancer research to develop faster and more effectively and The University of Nottingham and CEAC are grateful to Oncimmune for allowing CEAC this exclusive access to its technology which will allow researchers to continue to make market-leading, life-saving breakthroughs.